Physician profile
Roger Behar
NPI 1386685303
$87,207.65
in general payments reported to CMS, 2019-2025
58 companies · $8,636 in 2025
The $8,636 reported for 2025 was more than what 88% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $14K · 2021: $10K · 2022: $15K · 2023: $9,764 · 2024: $7,218 · 2025: $8,636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $5,310 · Travel and Lodging: $229 · Education: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,931.25 |
| Food and Beverage | $5,310.01 |
| Travel and Lodging | $228.93 |
| Education | $148.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $43,610.96 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Genzyme Corporation | $28,604.11 | 2019-2025 | |
| Allergan, INC. | $8,429.71 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $2,431.50 | 2019-2025 | |
| Eisai INC. | $425.58 | 2024-2025 | |
| Lilly USA, LLC | $365.97 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Emd Serono, INC. | $358.38 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $330.11 | 2019-2025 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $296.35 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Pfizer INC. | $251.43 | 2023-2025 | |
| Biogen, INC. | $222.73 | 2019-2025 | Vumerity, Tysabri |
| Kyowa Kirin, INC. | $123.86 | 2019-2021 | |
| Argenx US, INC. | $110.05 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Amneal Pharmaceuticals LLC | $109.85 | 2019-2025 | Crexont, Ongentys, Rytary |
| Lundbeck LLC | $95.59 | 2019-2025 | Rexulti, Vyepti |
Show all 57 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Behar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.